Retatrutide vs Semaglutide: Results, Risks, Cost

Retatrutide posted the largest weight loss of any obesity drug in a completed trial. Semaglutide is the drug a pharmacist can hand you this afternoon with a prescription, a label, a missed-dose rule and four years of outcomes data behind it.

If you want the biggest number, retatrutide leads by roughly 9 percentage points in cross-trial terms. If you want a regulated drug with proven heart protection you can start under a prescriber this month, semaglutide is the only one of the two that qualifies. The rest of this page shows where those numbers come from and where they break down.

Think of a bathtub. Semaglutide turns the tap down, so fewer calories come in. Retatrutide turns the tap down and also pulls the plug, so calories drain faster at the same time.

Literally stated: semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, blunts appetite and improves insulin release after meals; its weight effect comes from eating less. Retatrutide activates three receptors, GIP, GLP-1 and glucagon, and in preclinical models the glucagon component raised energy expenditure on top of the appetite effect (Coskun et al., Cell Metab, 2022, PMID 35985340).

The glucagon receptor also acts on the liver. In a 48-week substudy of people with fatty liver disease, retatrutide cut liver fat by more than 80% on average at the 8 mg and 12 mg doses by week 24, with most participants reaching a normal liver-fat level (Sanyal et al., Nat Med, 2024, PMID 38858523). Semaglutide reduces liver fat too, through weight loss, but without a direct glucagon signal.

The third receptor explains the gap in the trial results. It also explains why retatrutide carries signals semaglutide does not: glucagon raises heart rate and blood glucose in the short term, which is why the phase 2 trial watched both closely.

The headline numbers come from different trials, so the fair comparison lines them up by week rather than by press release.

In the phase 2 trial, 338 adults with obesity took retatrutide or placebo once weekly for 48 weeks. Mean weight change at 24 weeks was 17.5% on 12 mg, 17.3% on 8 mg and 12.9% on 4 mg; at 48 weeks it was 24.2%, 22.8% and 17.1%, against 2.1% on placebo. At 48 weeks, 100% of the 12 mg group had lost at least 5% and 83% had lost at least 15% (Jastreboff et al., N Engl J Med, 2023, PMID 37366315).

STEP 1 enrolled 1,961 adults without diabetes and ran 68 weeks. Mean weight change was 14.9% on semaglutide 2.4 mg against 2.4% on placebo; 86.4% lost at least 5%, 69.1% at least 10% and 50.5% at least 15% (Wilding et al., N Engl J Med, 2021, PMID 33567185). The week-20 figure of 10.6% comes from the STEP 4 run-in, where 902 adults were titrated to 2.4 mg before randomization (Rubino et al., JAMA, 2021, PMID 33755728).

Read side by side: at roughly five months, retatrutide 12 mg was ahead by about 7 percentage points. At the end of each trial it was ahead by about 9, and retatrutide had not plateaued at week 48. The week-by-week shape of the semaglutide curve is in semaglutide results week by week; the retatrutide shape in how long retatrutide takes to work.

Both drugs share one dominant problem: the gut. The difference is that semaglutide's numbers come from thousands of patients and a label, while retatrutide's come from one phase 2 trial and a company phase 3 announcement.

In the retatrutide trial, gastrointestinal events were the most common adverse events, were dose-related, were mostly mild to moderate, and were partially mitigated by starting at 2 mg rather than 4 mg (Jastreboff et al., N Engl J Med, 2023, PMID 37366315). In STEP 1, nausea and diarrhea were the most common events, typically transient, and 4.5% of the semaglutide group stopped treatment because of them, against 0.8% on placebo (Wilding et al., N Engl J Med, 2021, PMID 33567185).

The timing is the same for both. Across the pooled STEP trials, GI events clustered during and just after each dose escalation and faded with time (Wharton et al., Diabetes Obes Metab, 2022, PMID 34514682). Hour-by-hour management is in the retatrutide nausea guide and how to relieve nausea from semaglutide; the class-wide rates are in GLP-1 side effect statistics.

Both are once-weekly subcutaneous injections climbing in 4-week steps. Semaglutide takes 16 weeks to reach its ceiling; retatrutide, in the trial protocol, took about 12.

The milligram numbers are not comparable across drugs; 12 mg of retatrutide is not "five times" 2.4 mg of semaglutide, because the two molecules bind different receptors at different potencies. The semaglutide steps are laid out in the semaglutide titration schedule and converted to pen clicks or units in the semaglutide dosage calculator.

Retatrutide adds a step semaglutide users never face: the vial arrives as powder. Mixing and storage are in how to reconstitute retatrutide, and the retatrutide dosage calculator turns milligrams into syringe units at your concentration. The 2 mg start is the single most protective choice available; the phase 2 groups that started at 4 mg had more GI events than those that started at 2 mg and climbed.

Half-lives are close. Retatrutide's is about 6 days (Urva et al., Lancet, 2022, PMID 36354040); semaglutide's clearance and volume of distribution put it at roughly 1 week (Overgaard et al., Diabetes Ther, 2019, PMID 30788808). Both forgive a few hours of drift and punish a doubled dose. Injection timing is covered in best time to take retatrutide.

Semaglutide has three FDA-approved products and a published price. Retatrutide has a trial program and a grey market.

The research-grade price is the trap. A $200 vial of retatrutide looks cheaper than a $349 Wegovy fill, but you are comparing a regulated drug with a certificate of analysis you have to request from a vendor, no sterility guarantee and no prescriber. Where that money goes and what it buys is broken down in retatrutide cost; the full GLP-1 price landscape, including the coming Novo price cuts, is in GLP-1 cost statistics.

Timeline: the TRIUMPH phase 3 program covers eight trials and more than 5,800 patients, and approval cannot come before the main obesity trials read out and the FDA reviews the file. Current estimates are tracked in when will retatrutide be available.

Choose on what you can obtain legally and what your body needs, in that order.

Semaglutide is the right choice if you:

• Need an approved drug with a prescriber, a label and a missed-dose rule
• Have cardiovascular disease, where SELECT showed a 20% reduction in major events
• Want the longest safety record in the class and the option of an oral form
• Have insurance coverage, or can use the $349 self-pay program
• Are early in treatment and have not yet reached 2.4 mg or given it 68 weeks

Retatrutide is worth watching if you:

• Lost less than 10% on 2.4 mg of semaglutide after a full titration and 6 months at the top dose
• Have significant liver fat, where the glucagon signal adds a direct effect
• Are willing to wait for approval or qualify for a TRIUMPH trial site
• Understand that any vial sold today is unapproved research material with no human-use clearance

A plateau on semaglutide is common and usually has fixable causes before you need a stronger drug; not losing weight on semaglutide walks through them. Do not treat 12 mg of retatrutide as the next rung on a ladder you can climb at will. It is a trial drug with a heart-rate signal and no outcomes data.

No trial has studied this switch. What follows is pharmacology plus the convention the research community borrowed from switching from tirzepatide to retatrutide.

1. 1.Take your last semaglutide dose on your usual day. Do not taper it; a weekly drug tapers itself.
2. 2.Wait the normal 7 days. The first retatrutide injection goes in on the day the next semaglutide dose would have been due.
3. 3.Start at 2 mg regardless of your semaglutide dose. There is no conversion table, and the 2 mg start was the most protective arm in the phase 2 trial.
4. 4.Hold each step 4 weeks. 2, 4, 8, then 12 mg if needed.
5. 5.Expect a soft week 1 to 2. Semaglutide is still 50% present a week after the last dose; appetite suppression carries over, so the first retatrutide weeks feel like a continuation, not a restart.

Scenario 1, the stack. You inject your last 2.4 mg on Friday, read about retatrutide on Sunday, and inject 4 mg on Monday. With a roughly 1-week half-life, about 75% of the semaglutide is still circulating. Two gut-slowing agonists now overlap at the dose level where retatrutide's phase 2 participants had the most GI events. Expect vomiting and a missed week of work. Fix: the first retatrutide dose waits for the next Friday, and it is 2 mg.

Scenario 2, the "equivalent" dose. You reason that 2.4 mg is semaglutide's top dose, so retatrutide should start at its top dose, 12 mg. The trial reached 12 mg only after 12 weeks of stepping through 2, 4 and 8 mg; no one started there. A cold 12 mg is a four-step jump, the kind that produces the vomiting and dehydration that end up in emergency rooms. Fix: 2 mg, and use the retatrutide dosage calculator to draw it accurately.

Scenario 3, the long washout. You stop semaglutide for 6 weeks "to clear it." Semaglutide is essentially gone after 5 weeks, which is the problem: in STEP 4, participants switched from 2.4 mg to placebo regained 6.9% of body weight over 48 weeks while those who continued lost a further 7.9% (Rubino et al., JAMA, 2021, PMID 33755728). Appetite returns within 2 to 3 weeks of the last dose. Fix: a 7-day gap, not a washout. How long the drug lingers is in how long semaglutide stays in your system.

Retatrutide is investigational and not FDA-approved. Switching to it means leaving a regulated drug for research material, and that decision belongs with a prescriber who knows your history.